BR112014023107A2 - - Google Patents

Info

Publication number
BR112014023107A2
BR112014023107A2 BR112014023107A BR112014023107A BR112014023107A2 BR 112014023107 A2 BR112014023107 A2 BR 112014023107A2 BR 112014023107 A BR112014023107 A BR 112014023107A BR 112014023107 A BR112014023107 A BR 112014023107A BR 112014023107 A2 BR112014023107 A2 BR 112014023107A2
Authority
BR
Brazil
Application number
BR112014023107A
Other versions
BR112014023107B1 (pt
Inventor
Paul Andrew Ford
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014023107A2 publication Critical patent/BR112014023107A2/pt
Publication of BR112014023107B1 publication Critical patent/BR112014023107B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
BR112014023107-9A 2012-03-20 2013-03-19 Usos de derivados de pirazol, e composição farmacêutica BR112014023107B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613187P 2012-03-20 2012-03-20
US61/613,187 2012-03-20
PCT/EP2013/055730 WO2013139809A1 (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
BR112014023107A2 true BR112014023107A2 (pt) 2017-06-20
BR112014023107B1 BR112014023107B1 (pt) 2021-08-10

Family

ID=47901996

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023107-9A BR112014023107B1 (pt) 2012-03-20 2013-03-19 Usos de derivados de pirazol, e composição farmacêutica

Country Status (30)

Country Link
US (2) US9339491B2 (pt)
EP (1) EP2827860B1 (pt)
JP (1) JP6091593B2 (pt)
KR (1) KR101793777B1 (pt)
CN (1) CN104203234B (pt)
AU (1) AU2013237503B2 (pt)
BR (1) BR112014023107B1 (pt)
CA (1) CA2866108C (pt)
CL (1) CL2014002471A1 (pt)
CY (1) CY1118327T1 (pt)
DK (1) DK2827860T3 (pt)
ES (1) ES2605942T3 (pt)
HK (1) HK1200352A1 (pt)
HR (1) HRP20161514T1 (pt)
HU (1) HUE032004T2 (pt)
IL (1) IL234537A (pt)
LT (1) LT2827860T (pt)
MA (1) MA37455B1 (pt)
MX (1) MX351996B (pt)
NZ (1) NZ628392A (pt)
PH (1) PH12014502107A1 (pt)
PL (1) PL2827860T3 (pt)
PT (1) PT2827860T (pt)
RU (1) RU2625762C2 (pt)
SG (1) SG11201404941WA (pt)
SI (1) SI2827860T1 (pt)
TN (1) TN2014000350A1 (pt)
TW (1) TWI583381B (pt)
WO (1) WO2013139809A1 (pt)
ZA (1) ZA201405871B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600833C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронической обструктивной болезни легких
RU2600822C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронического обструктивного бронхита
CA3016488C (en) 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
WO2017153701A1 (en) * 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
US10331542B2 (en) * 2016-06-23 2019-06-25 International Business Machines Corporation System and method for detecting and alerting unexpected behavior of software applications
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
EP3585382B1 (en) 2017-12-11 2021-07-14 Mereo BioPharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452035B (zh) * 2003-06-26 2014-09-11 Novartis Ag 以5員雜環為主之p38激酶抑制劑
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TW201343162A (zh) 2013-11-01
CL2014002471A1 (es) 2015-01-09
KR20140146073A (ko) 2014-12-24
US20150031736A1 (en) 2015-01-29
TWI583381B (zh) 2017-05-21
US20160243081A1 (en) 2016-08-25
ES2605942T3 (es) 2017-03-17
HRP20161514T1 (hr) 2016-12-30
MA37455B1 (fr) 2017-03-31
RU2625762C2 (ru) 2017-07-18
LT2827860T (lt) 2016-12-12
PH12014502107B1 (en) 2014-12-10
JP2015510916A (ja) 2015-04-13
EP2827860A1 (en) 2015-01-28
AU2013237503A1 (en) 2014-09-25
SI2827860T1 (sl) 2017-01-31
PL2827860T3 (pl) 2017-09-29
US9339491B2 (en) 2016-05-17
NZ628392A (en) 2016-06-24
IL234537A (en) 2016-09-29
CA2866108A1 (en) 2013-09-26
MA37455A1 (fr) 2016-08-31
ZA201405871B (en) 2016-01-27
JP6091593B2 (ja) 2017-03-08
EP2827860B1 (en) 2016-10-26
BR112014023107B1 (pt) 2021-08-10
RU2014141893A (ru) 2016-05-10
PH12014502107A1 (en) 2014-12-10
HK1200352A1 (zh) 2015-08-07
CY1118327T1 (el) 2017-06-28
AU2013237503B2 (en) 2016-05-26
CA2866108C (en) 2017-03-07
MX351996B (es) 2017-11-06
DK2827860T3 (en) 2016-12-12
HUE032004T2 (en) 2017-08-28
WO2013139809A1 (en) 2013-09-26
CN104203234A (zh) 2014-12-10
SG11201404941WA (en) 2014-10-30
TN2014000350A1 (en) 2015-12-21
MX2014011291A (es) 2014-10-13
PT2827860T (pt) 2016-12-20
CN104203234B (zh) 2017-06-13
KR101793777B1 (ko) 2017-11-03

Similar Documents

Publication Publication Date Title
BR112014017635A2 (pt)
BR112014017614A2 (pt)
BR112014017853A2 (pt)
BR112014017625A2 (pt)
BR112014017659A2 (pt)
BR112014019109A2 (pt)
BR112014017646A2 (pt)
BR112014017638A2 (pt)
BR112014017607A2 (pt)
BR112014018047A2 (pt)
BR112013027865A2 (pt)
BR112014017634A2 (pt)
BR112014017609A2 (pt)
BR112014017673A2 (pt)
BR112014017644A2 (pt)
BR112014017647A2 (pt)
BR112014017588A2 (pt)
BR112014013184A8 (pt)
BR112014017618A2 (pt)
BR112014017630A2 (pt)
BR112014017652A2 (pt)
BR112014019110A2 (pt)
BR112014023107A2 (pt)
BR112014017621A2 (pt)
BR112014017622A2 (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2013, OBSERVADAS AS CONDICOES LEGAIS.